A vaccine expert breaks down everything you need to know about the Novavax vaccine.
The AstraZeneca vaccine was 70 per cent effective against symptomatic COVID-19 infection in a large multinational study, and recently reported 76 per cent overall efficacy against symptomatic COVID-19 in another large study done primarily in the United States.
THE CANADIAN PRESS/John Woods
How do we reasonably and accurately balance the risks of the AstraZeneca vaccine against the benefits? Conceptualising risk can be tricky, but the government's latest advice is sensible.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
Scientists have called it "vaccine-induced prothrombotic immune thrombocytopenia", or VIPIT. The condition is characterised by a shortage of platelets in the blood.
A mass vaccination hub in Genoa, Italy.
Luca Zennaro/EPA/AAP
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
Data from clinical trials and the real world COVID vaccine rollout suggest blood clots occur no more frequently in vaccinated people than they do in the general population.
The European Medicines Agency has found no link between thrombosis and the AstraZeneca vaccine, but precautionary investigations are continuing in some countries.
A COVID-19 vaccine is administered at a clinic at Olympic Stadium in Montréal on March 1, 2021, marking the beginning of mass vaccination in the Province of Québec based on age.
THE CANADIAN PRESS/Paul Chiasson
With four COVID-19 vaccines approved for use in Canada, it's time to answer FAQs about efficacy, immunity, eradication and variants.
By early March only one-third of Germany’s stocks of the Oxford/AstraZeneca vaccine had been used – possibly because of misinformation about its effects.
Sean Gallup/EPA-EFE
Visiting Professor in Biomedical Ethics, Murdoch Children's Research Institute; Distinguished Visiting Professor in Law, University of Melbourne; Uehiro Chair in Practical Ethics, University of Oxford